InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Explore the complete record of transactions filed by Landis John B., Director. Officer active across 1 company, notably EyePoint Pharmaceuticals, Inc.. Cumulatively, 3 reports have been logged. Activity tracked since 9 February 2022. The latest transaction was disclosed on 5 January 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations
John B. Landis serves as a Director at EyePoint Pharmaceuticals, Inc. He brings his expertise in corporate governance and strategy. His role as a director includes participating in board meetings and contributing to strategic decision-making for the company.